30 marzo 2017

PharmaMar Organiza el 1 de abril la 2ª Edición del Congreso “Soft Tissue Sarcoma: Evidence & Experience” .

 The European Society of Medical Oncology Recommends the Treatment of Sarcomas With Metastases With Yondelis ( Trabectedin ) .



* PharmaMar is conducting 17 post-authorization clinical trials with Trabectedin indicated for the treatment of adult with advanced Sarcoma

* Las Guías Clínicas de la Sociedad Europa de Oncología Médica Recomiendan Tratar el Sarcoma con Yondelis ( Trabectedin ) .

* Sarcoma: almost 50% of diagnosed patients present metastases or are expected to develop it shortly after cancer .

* Diagnoses of soft tissue sarcoma represent about 0.7% of all new cancer cases in the US, and account for 7-10% of paediatric cancers.

* Soft tissue sarcoma (STS) is a rare cancer, and between 4 and 5 cases per 100,000 adults are newly diagnosed in Europe each year.

* Cerca del 50% de los pacientes con sarcoma de tejidos blandos presenta metástasis o se espera que la desarrollen.

* Aunque el sarcoma de tejidos blandos puede aparecer en cualquier parte, se produce con mayor frecuencia (43%) en brazos y piernas .

* El Sarcoma es considerado un tumor raro. Cada año aparecen en Europa 4-5 nuevos casos cada 100.000 habitantes .